Profil bibliographique

X J Wang

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

4Publications signalées

23Citations signalées

1Affiliations récentes

Les institutions déclarées

Les domaines associés

HER2/EGFR in Cancer ResearchCancer Treatment and PharmacologyCancer Immunotherapy and BiomarkersCancer Cells and MetastasisNanoplatforms for cancer theranostics

Les publications récentes

2026 conference-abstract OpenAlex

Effectiveness and safety of traditional Chinese medicine external wash combined with local cooling in preventing UTD1-induced peripheral neuropathy in breast cancer patients: A single-arm, phase II preliminary study.

X J Wang, Xiying Shao, Lu Gao, Y.‐S. LAI et autres

50 Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a prevalent and debilitating toxicity associated with many anticancer agents, frequently leading to dose reduction, treatment delay, or even discontinuation, thereby compromising clinical outcomes. For patients with advanced breast cancer receiving utidelone (UTD1), a next-generation …

cn (code pays fourni par la source)

0 citations Journal of Clinical Oncology

2025 article OpenAlex

[Phase Ⅲ, multicenter, randomized comparative study of LY01005 and Zoladex® for patients with premenopausal breast cancer].

Xinyu Shao, Qinxin Zhang, Zhaofeng Niu, M. LI et autres

in suppressing E2 to menopausal levels in Chinese patients with premenopausal breast cancer, with a similar safety profile.

cn (code pays fourni par la source)

0 citations PubMed

2023 other OpenAlex

[A real-world study on the efficacy and safety analysis of paclitaxel liposome in advanced breast cancer].

Chuang Sun, S S Wang, J B Li, Y S Wang et autres

Paclitaxel liposomes is widely used and has promising efficacy in multi-subtype advanced breast cancer.

cn (code pays fourni par la source)

3 citations PubMed

2020 article OpenAlex

[Phase Ⅲ randomized controlled, multicenter, prospective study of recombinant anti-HER2 humanized monoclonal antibody (Cipterbin) combined with vinorelbine in patients with HER2 positive metastatic breast cancer: the HOPES Study].

Li Bian, Binghe Xu, Lei Di, T Wang et autres

The recombinant anti-HER2 humanized monoclonal antibody (Cipterbin) combined with vinorelbine has significant efficacy and good safety. It is the optimized therapy regime for patients with taxane-pretreated HER2 positive metastatic breast cancer, which provides more targeted therapy opportunities for HER2 positive breast cancer …

cn (code pays fourni par la source)

20 citations PubMed

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.